Company to showcase innovative programs
addressing urgent need for disease-modifying therapies selectively
targeting toxic oligomers in Alzheimer's and Parkinson's diseases
and ALS
TORONTO and CAMBRIDGE, MA, March
26, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX:
PMN) (OTCQB: ARFXF), a biotechnology company focused on the
discovery and development of antibody therapeutics selectively
targeting toxic oligomers implicated in the development of
neurodegenerative diseases, announced that it will participate in
the Microcap Spring Investor Summit.
Eugene Williams, ProMIS'
Executive Chairman will provide an overview of the company's novel
drug discovery and development programs for Alzheimer's disease,
Parkinson's disease and ALS (amyotrophic lateral sclerosis) on
Tuesday, April 2, 2019 at
11:00am, ET, at The Essex House in
New York.
Company slides and a live video webcast of Mr. Williams'
presentation will be available at the following link:
https://www.webcaster4.com/Webcast/Page/2038/29929.
Following the event, the webcast and presentation will be archived
for one year through the same link.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc.
is a development stage biotechnology company focused on discovering
and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular Alzheimer's disease (AD),
amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
The Company's proprietary target discovery platform is based on the
use of two complementary thermodynamic, computational discovery
engines -ProMIS and Collective Coordinates – to predict novel
targets known as Disease Specific Epitopes on the molecular surface
of misfolded proteins. Using this unique precision approach, the
Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto,
Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on
the Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF.
Visit us at www.promisneurosciences.com or follow us
on Twitter and LinkedIn
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This
information release contains certain forward-looking information.
Such information involves known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-to-participate-in-microcap-spring-investor-summit-2019-300818146.html
SOURCE ProMIS Neurosciences Inc.